DiNardo, C. D., De Botton, S., Stein, E. M., Roboz, G. J., Mims, A. S., Pollyea, D. A., … Kantarjian, H. M. (2017). Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. In BLOOD (Vol. 130). Atlanta, GA: AMER SOC HEMATOLOGY.

DiNardo, Courtney D., Stephane De Botton, Eytan M. Stein, Gail J. Roboz, Alice S. Mims, Daniel A. Pollyea, Ronan T. Swords, et al. “Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study.” In BLOOD, Vol. 130. AMER SOC HEMATOLOGY, 2017.

DiNardo CD, De Botton S, Stein EM, Roboz GJ, Mims AS, Pollyea DA, et al. Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. In: BLOOD. AMER SOC HEMATOLOGY; 2017.

DiNardo, Courtney D., et al. “Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study.” BLOOD, vol. 130, AMER SOC HEMATOLOGY, 2017.

DiNardo CD, De Botton S, Stein EM, Roboz GJ, Mims AS, Pollyea DA, Swords RT, Altman JK, Collins RH, Mannis GN, Uy GL, Donnellan W, Pigneux A, Fathi AT, Stein AS, Erba HP, Prince GT, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Yen K, Kapsalis SM, Liu H, Goldwasser M, Agresta S, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. BLOOD. AMER SOC HEMATOLOGY; 2017.